Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Status and phase

Completed

Phase 1

Conditions

Persistent/Recurrent Minimal Residual Disease (MRD)

Acute Lymphoblastic Leukemia

Complete Hematologic Remission (CHR)

Treatments

Other: Autologous NK cells infusions

Study type

Interventional

Funder types

Other

Identifiers

NCT02185781

LAL 2013

Details and patient eligibility

About

The present study aims at studying how safe and tolerable a new therapy for patients with Acute Lymphoblastic Leukemia (ALL) is.

This new therapy consists of an immunotherapy, that is an approach focusing on the immune system, and it targets ALL patients in complete remission but who may still have the disease at a cellular level (this is called 'minimal residual disease').

For any further information, please, discuss with your treating physician.

Full description

This is an open label, multicenter, phase I study of adoptive immunotherapy with enriched and expanded autologous natural killer (NK) cells for patients with Ph+ acute lymphoblastic leukemia (ALL) in complete hematologic remission (CHR) but with persistent/recurrent minimal residual disease (MRD) ≥60 years or not eligible for other post-CHR treatment modalities.

The study will investigate the safety and tolerability of a new type of NK-based immunotherapy based on the infusion of escalating doses of ex-vivo expanded autologous NK cells in Ph+ ALL patients. A maximum of 6 patients will be enrolled in two different steps. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive tyrosine kinase inhibitor (TKI) maintenance.

Enrollment

6 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult subjects with Ph+ ALL in CHR (1st or 2nd) with MRD positivity confirmed at baseline, older or equal to 60 years or not eligible for other post-CHR treatment modalities.
WHO score 0-1.
Hematopoietic, liver and renal normal functions defined as follows:

WBC bigger or equal to 2.000/mm3 lymphocytes bigger or equal to 500/mm3 neutrophils bigger or equal to 1.000/mm3 platelets bigger or equal to 50.000/mm3 Hb bigger or equal to 9 g/dl creatinine fewer or equal to 1.5 x ULN bilirubin fewer or equal to 1.5 x ULN AST and ALT less than 3 times the upper limit of normal. LDH less than 2 times the upper limit of normal.

For male and female subjects of childbearing potential, agreement to use effective contraception.
Authorization by Istituto Superiore di Sanità (ISS) according to DM 2 March 2004.
Signed written informed consent according to ICH/EU/GCP and national local regulations.

Exclusion criteria

Concurrent chemotherapy or immunotherapy (TKI maintenance is permitted).
Any contraindications to perform a leukapheretic procedure for mononuclear cell collection.
Active or chronic infection, including Treponema, HIV, HBV and/or HCV unless antigen/PCR negative.
Presence of autoimmune symptoms.
Pregnant or lactating females.
Simultaneous participation in another clinical trial.
Any physical or psychological impediment in a patient that could lead the investigator to suspect his/her poor compliance to the protocol.